UNSPSC 51111665: Thioguanine or tioguanine

This classification denotes a purine antagonist and amidophosphoribosyltransferase inhibitor with the molecular formula C5H5N5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FTK8U1GZNX, chemically known as 6h-purine-6-thione, 2-amino-1,7-dihydro- but generally known as thioguanine, which bears US NIH Compound Identifier 2723601. European Medicines Agency schedules Tioguanine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11084MIG.

World Health Organization schedules thioguanine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, THIOGUANINE remains the US FDA Preferred Term for this commodity. Thioguanine bears US NLM identifiers UMLS ID C0039902 and NCI Concept Code C876. SMILES: S=C1NC([NH]C2NC[NH]C12)N.

UNSPSC 51111665 Thioguanine or tioguanine is a Commodity code representing a specific pharmaceutical active ingredient used in cancer treatment and other clinical applications. State and local governments purchase thioguanine primarily through their Medicaid pharmacy benefit programs, employee health plans, and institutional healthcare procurement channels. The code applies to the chemical compound itself as a finished pharmaceutical product rather than bulk chemical precursors or manufacturing inputs. State health and human services agencies, county hospital systems, and regional health plans constitute the primary buyers, though activity tends to concentrate among state Medicaid authorities and state employee health benefit programs that manage large-volume pharmacy benefit purchasing on behalf of enrolled populations.

Recent state and local procurement activity under this code is minimal. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program, which seeks to establish direct contracting relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to streamline prescription fulfillment and cost management. The RFI focuses on vendors' capacity to negotiate direct contracts with self-insured employers and government health plans outside traditional pharmacy benefit manager and group purchasing organization channels, using negotiated net pricing models. This represents exploratory market intelligence gathering rather than a formal competitive solicitation, and the state indicated it will develop detailed procurement specifications following vendor responses. Beyond this single Texas HHS activity, the source reports no other recent state or local thioguanine procurement opportunities, suggesting limited current activity under the code.